Stockreport

Contineum Therapeutics GAAP EPS of -$0.45 [Seeking Alpha]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF Contineum believes it should have sufficient cash resources to fund its planned operations through 2028. More on Contineum Therapeutics Seeking Alpha's Quant Rating [Read more]